Basilea berichtet auf ESMO-Meeting über klinischen Nutzen des Medikamentenkandidaten Derazantinib bei Patienten mit intrahepatischem Cholangio­karzinom (iCCA) und verschiedenen FGFR2-Genaberrationen

NEXT STORY
Novartis announces positive results from Phase III PALLADIUM study of inhaled combination QMF149 in patients with uncontrolled asthma
PREV STORY
FDA approves Roche’s Rituxan (rituximab) in children with two rare blood vessel disorders
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Sanofi and Regeneron to accelerate and expand investment for cemiplimab and dupilumab development programs

  Press ReleaseSource: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi and Regeneron to accelerate and ...

author_avatar
NASDAQ Market News

Aquinox to Present at Jefferies 2017 Global Healthcare Conference

VANCOUVER, British Columbia, June 01, 2017 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), ...

author_avatar
NASDAQ Market News

Dendritic Cell Vaccine Inhibits Tumor Progression in Preclinical Liver Cancer Model

NEW YORK, Feb. 25, 2016 (GLOBE NEWSWIRE) -- Saronic Biotechnology, Inc. today announces publication ...

author_avatar
NASDAQ Market News